Vendor review steps common to pain management and PM&R groups
Pain management and physical medicine practices that evaluate a new tissue or exosome supplier commonly request a donor eligibility and screening summary, a certificate of analysis tied to the specific lot, and a description of how the product was tested before release. Groups that run procedures across more than one Milwaukee-area location often centralize this documentation so any site can produce it during an internal or payer audit.
Milwaukee
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
166- Pain Medicine
- 60
- Physical Medicine & Rehabilitation
- 106
NPI-based account setup
An NPI number is required to verify a Precision Biologics account, which fits how most pain management and PM&R groups already organize ordering by practice rather than by individual clinician. A verified account can request documentation and place orders for any product in the Wharton's jelly or exosome lines without resubmitting credentials each time.
Receiving shipments in the upper Midwest
Cryopreserved Wharton's jelly formats arrive overnight on dry ice in validated containers; a Milwaukee practice should check the container and lot number against the packing slip on arrival and log that lot number against the certificate of analysis. Lyophilized exosome formats are shelf-stable and ship without the same cold-chain handling, which can simplify receiving for practices without daily deliveries.
Checking regulatory standing before adding a product
A practice should confirm its own standing with the Wisconsin Medical Examining Board and discuss the intended use of any new product with its own counsel before incorporating it into its service line. FDA has stated there are no FDA-approved exosome products, and exosome products are generally regulated as biologic drugs rather than under the 361 HCT/P framework that covers some Wharton's jelly products; this distinction is worth raising directly with counsel. Precision Biologics can arrange a documentation-focused peer-to-peer call for a practice's medical director but does not advise on dosing or protocols.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Can a pain management group with multiple Milwaukee-area locations use one Precision Biologics account?+
Account structure is handled case by case; a group should discuss how its locations and NPI numbers should map to account verification when applying.
Are Wharton's jelly products the same as stem cell therapy?+
No. Published evaluations of commercial Wharton's jelly allografts have found low viable cell counts and rare or absent colony-forming stem cells, so these products should not be described or sold as stem cell therapies.
How do we confirm a lot's sterility testing before use?+
Each lot is held in quarantine pending third-party sterility testing and internal release criteria; the certificate of analysis documenting that testing is available on request.